Chenodeoxycholic Acid Market Size, Share, Growth, and Industry Analysis, By Type (80-90% Purity, 95-98% Purity) By Application (Ursodeoxycholic Acid Synthesis, Steroids and Steroid Derivatives) Regional Forecast From 2025 To 2034

•   
•   
  

  Request a Free sample to learn more about this report

    

CHENODEOXYCHOLIC ACID MARKET OVERVIEW

The global Chenodeoxycholic Acid Market size stood at USD 0.43 billion in 2025, growing further to USD 0.9 billion by 2034 at an estimated CAGR of 8.47% from 2025 to 2034.

The United States Chenodeoxycholic Acid Market size is projected at USD 0.13978 billion in 2025, the Europe Chenodeoxycholic Acid Market size is projected at USD 0.12023 billion in 2025, and the China Chenodeoxycholic Acid Market size is projected at USD 0.11162 billion in 2025.

The COVID-19 pandemic has been unprecedented and staggering, with chenodeoxycholic acid experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

Chenodeoxycholic acid (CDCA) is a bile acid that plays a crucial role in digestion and the metabolism of cholesterol in the human body. It is synthesized from cholesterol in the liver and released into the bile, which aids in the digestion and absorption of dietary fats. CDCA is a primary bile acid, meaning it is directly synthesized by the liver, and it is one of the main components of bile along with cholic acid. CDCA functions as a natural detergent in the digestive system, emulsifying dietary fats and aiding in their breakdown and absorption. It helps solubilize cholesterol and fat-soluble vitamins, facilitating their absorption in the small intestine. Moreover, CDCA plays a vital role in cholesterol homeostasis. It is involved in a feedback mechanism that regulates cholesterol synthesis in the liver. When levels of CDCA are high, it inhibits the production of cholesterol by suppressing the enzyme cholesterol 7-alpha-hydroxylase, which is responsible for its synthesis.

The chenodeoxycholic acid market is experiencing steady growth due to its wide range of applications in the pharmaceutical and healthcare sectors. Chenodeoxycholic acid, also known as CDCA, is a bile acid naturally produced in the liver and plays a crucial role in the digestion and absorption of dietary fats. It is commonly used as an active pharmaceutical ingredient in the treatment of gallstones, primary biliary cholangitis, and other liver-related disorders. The global market for chenodeoxycholic acid is expected to witness significant growth in the coming years due to its therapeutic properties and increasing demand in the healthcare industry.

KEY FINDINGS

COVID-19 IMPACT

Pandemic Led to Supply Shortages Impeding the Market Growth

The Covid-19 pandemic has had a mixed impact on the chenodeoxycholic acid market. On one hand, the demand for pharmaceutical products, including chenodeoxycholic acid-based medications, witnessed a surge due to the need for treatments and therapies related to liver diseases. The increased focus on maintaining overall health and strengthening the immune system also contributed to the demand for chenodeoxycholic acid supplements. However, the disruptions in the global supply chain, restrictions on international trade, and the temporary shutdown of manufacturing facilities had an adverse effect on the production and distribution of chenodeoxycholic acid. These factors led to supply shortages and increased prices, affecting the market growth to some extent.

LATEST TRENDS

Growing Preference for Natural and Organic Formulations in The Pharmaceutical Industry to Boost the Market Development

Consumers are becoming more conscious of the potential side effects of synthetic drugs and are seeking natural alternatives for their health concerns. As chenodeoxycholic acid is a naturally occurring bile acid, it is considered a safer option compared to synthetic drugs. This trend is expected to drive the demand for chenodeoxycholic acid-based medications and supplements in the coming years.

• According to insights, manufacturers report multi-tonne annual output capability for bile-acid APIs (including CDCA), reflecting industrial-scale supply rather than solely small-batch production.

• According to data, planned/installed capacity expansions cite specific capacities such as 460 tonnes annual potential CDCA output at select new Shandong facilities, highlighting large domestic capacity build-outs.

•   
•   
  

  Request a Free sample to learn more about this report

    

CHENODEOXYCHOLIC ACID MARKET SEGMENTATION

By Type Analysis

According to type, the market can be segmented into 80-90% purity, 95-98% purity. 80-90% Purity being the leading segment of the market by type analysis.

By Application Analysis

Based on application, the market can be divided into ursodeoxycholic acid synthesis, steroids and steroid derivatives. Ursodeoxycholic acid synthesis being the leading segment of the market by application analysis.

DRIVING FACTORS

Increasing Prevalence of Liver Diseases to Drive the Market Growth

The rising prevalence of liver diseases, such as gallstones, primary biliary cholangitis, and non-alcoholic fatty liver disease (NAFLD), is a major driver for the chenodeoxycholic acid market. Liver diseases pose a significant burden on global healthcare systems and are a leading cause of morbidity and mortality worldwide. Factors such as sedentary lifestyles, unhealthy dietary habits, obesity, and the increasing prevalence of metabolic syndrome contribute to the growing incidence of liver diseases. Chenodeoxycholic acid plays a critical role in the treatment of various liver disorders. It is widely used for the dissolution of gallstones, a condition characterized by the formation of hardened deposits in the gallbladder. Chenodeoxycholic acid helps to dissolve gallstones by promoting the solubilization of cholesterol, the main component of gallstones. This therapeutic application of chenodeoxycholic acid provides a non-invasive alternative to surgical procedures for the management of gallstone-related complications.

Advancements in Pharmaceutical Research and Development to Drive the Market Development

Advancements in pharmaceutical research and development are playing a crucial role in driving the chenodeoxycholic acid market. Researchers are exploring the potential therapeutic applications of chenodeoxycholic acid beyond its traditional use in gallstone dissolution and treatment of primary biliary cholangitis. These ongoing research activities are expanding the scope of chenodeoxycholic acid and creating new opportunities for market growth. One area of research focus is liver regeneration. Chenodeoxycholic acid has been found to stimulate liver cell growth and regeneration in preclinical studies. This has significant implications for liver transplantation, liver injury repair, and the treatment of liver diseases where liver regeneration is a key factor. The development of chenodeoxycholic acid-based therapies that can promote liver regeneration may revolutionize the field of hepatology and offer new hope for patients with liver disorders.

• According to the research, regulatory recognition of CDCA for rare-disease therapy (Ctexli approval on Feb 21, 2025) creates formal prescribing pathways and orphan exclusivity windows that drive demand for regulated CDCA APIs.

• According to data, CDCA is a primary bile acid (C₄H₄₀O₄) with established mechanisms for dissolving cholesterol gallstones and altering bile composition — a biochemical profile that sustains at least 2 major therapeutic uses (gallstone dissolution and certain hepatic/metabolic disorders).

RESTRAINING FACTOR

Stringent Regulatory Landscape to Hamper the Market Growth

As chenodeoxycholic acid is primarily used as an active pharmaceutical ingredient (API), it is subject to strict regulatory approvals and quality control measures. The manufacturing, distribution, and use of pharmaceutical products are heavily regulated to ensure patient safety and product efficacy. Manufacturers of chenodeoxycholic acid must adhere to Good Manufacturing Practices (GMP) and comply with guidelines set by regulatory authorities such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe. Meeting regulatory requirements and obtaining the necessary approvals can be a complex and time-consuming process for manufacturers. They must demonstrate the quality, safety, and effectiveness of their chenodeoxycholic acid products through rigorous testing, documentation, and submission of data to regulatory agencies.

• According to the FDA prescribing information, CDCA treatment requires baseline and annual liver function testing (and testing “as clinically indicated”) because of liver-toxicity warnings, which limits easy outpatient uptake.

• According to regulatory label comparisons (FDA/EMA literature), CDCA metabolism elevates certain lithocholic acid metabolites at steady state versus ursodeoxycholic acid, creating measurable safety monitoring requirements that reduce usage in patients with impaired bile-acid sulfation.

•   
•   
  Request a Free sample to learn more about this report

    

CHENODEOXYCHOLIC ACID MARKET REGIONAL INSIGHTS

High Prevalence of Liver Diseases in North America to Bolster the Market Development in The Region

North America is a prominent region in the chenodeoxycholic acid market, expected to dominate the industry. This dominance can be attributed to several factors, including the high prevalence of liver diseases in the region. Liver diseases, such as gallstones, primary biliary cholangitis, and non-alcoholic fatty liver disease (NAFLD), are a significant healthcare concern in North America. The increasing incidence of these conditions has created a demand for effective treatments, driving the growth of the chenodeoxycholic acid market. Moreover, North America boasts a well-developed healthcare infrastructure that supports advanced research and development activities. The presence of established pharmaceutical companies and academic institutions specializing in the field of liver disease research further strengthens the market in the region. These entities contribute to the innovation and development of chenodeoxycholic acid-based medications and therapies, catering to the specific needs of patients with liver disorders.

Asia Pacific is poised to witness significant growth in the chenodeoxycholic acid market, driven by various factors unique to the region. One of the key factors contributing to the growth is the rising healthcare expenditure in countries like China, Japan, and India. As these countries focus on improving healthcare infrastructure and access to quality medical services, there is an increased demand for advanced treatments, including chenodeoxycholic acid-based therapies. Furthermore, the growing awareness about liver diseases in Asia Pacific has led to an increased diagnosis and treatment-seeking behavior among the population. Liver diseases, including viral hepatitis, alcoholic liver disease, and NAFLD, have become a major health concern in the region. This rising awareness has resulted in higher demand for medications and treatments that can effectively manage these conditions, thereby driving the market for chenodeoxycholic acid.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

• Guanghan Yikang Biological — Listed among leading CDCA API suppliers in recent market reports as a named top-player .

• ICE Group / ICE Pharma — According to ICE’s product pages, ICE manufactures CDCA under GMP with product lines that report multi-tonne output capability for bile-acid APIs.

List of Top Chenodeoxycholic Acid Companies

• Guanghan Yikang Biological
• ICE Group
• Linyi Tianli Biochemical
• Zhongshan Belling Biotechnology
• Tianjin NWS Biotechnology and Medicine
• Daewoong
• Shandong Zhongjing Biological
• PharmaZell GmbH
• Changde Yungang Biotechnology

REPORT COVERAGE

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.